Treats hypertension. ANDA 78414, held by Oxford Pharmaceuticals. Amlodipine Besylate.
As of Nov 21, 2026, ANDA 78414 (Amlodipine Besylate), held by Oxford Pharmaceuticals, was first approved by FDA on Apr 7, 2010, with 5 approved supplements and 0 published complete response letters.
Amlodipine besylate tablets are a calcium channel blocker and may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of: Hypertension Amlodipine besylate tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. Coronary Artery Disease Chronic Stable Angina Vasospastic Angina (Prinzmetal's or Variant Angina) Angiographically Documented Coronary Artery Disease in patients without heart failure or an ejection fraction < 40% 1.1 Hypertension
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 7, 2010 | Original application | Approved | None posted |
| Amlodipine BesylateEQ 2.5MG BASE · tablet;oral | Amlodipine Besylate | Rx |
| Amlodipine BesylateEQ 5MG BASE · tablet;oral | Amlodipine Besylate | Rx |
| Amlodipine BesylateEQ 10MG BASE · tablet;oral | Amlodipine Besylate | Rx |
| Apr 2, 2018 | Supplement 13Labeling · Standard review | Approved | None posted |
| Sep 18, 2015 | Supplement 3Labeling | Approved | None posted |
| Sep 18, 2015 | Supplement 7Labeling · Standard review | Approved | None posted |
| Sep 18, 2015 | Supplement 11Labeling · Standard review | Approved | None posted |
| Apr 30, 2010 | Supplement 2Labeling | Approved | None posted |
| Apr 7, 2010 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters